Bibliografia

  1. Auran JD, Stan MB. Jakobiec FA – Acanthamoeba keratitis. A review of the literature. Cornea 6: 2-26; 1987
  2. Bang S, Edell E, Eghrari AO, Gottsch JD – Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. Am.J.Ophthalmol. 149: 66-69; 2010
  3. Dart JKG, Saw VPJ, Kilvington S – Acanthamoeba keratitis: Diagnosis and Treatment- Update 2009. Am.J.Ophthalmol. 148: 487-499; 2009
  4. D’Aversa G, Stern GA, Driebe WT.- Diagnosis and successful medical treatment of Acanthamoeba keratitis. Arch.Ophthalmol. 113: 1120-1123; 1995
  5. De Freitas D – Newer antifungal agents (Relazione). World Cornea Congress, Boston, 7-9 Aprile 2010
  6. Duguid IG, Dart JK, Morlet N, Allan BD, Matheson M, Ficker L, Tuft S – Outcome of Acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Ophthalmology 104: 1587-1592; 1997
  7. Elder MJ, Kilvington S, Dart JKG – A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis. Invest.Ophthalmol.Vis.Sci. 35: 1059-1064, 1994
  8. Elder MJ, Dart JKG – Chemotherapy for Acanthamoeba keratitis. Lancet 345: 791-792; 1995
  9. Gatti S, Cevini C, Bruno A, Penso G, Rama P, Scaglia M. In vitro effectiveness of povidone-iodine on Acanthamoeba isolates from human cornea. Antimicrob Agents Chemother 42: 2232-4; 1998.
  10. Hay J, Kirkness CM, Seal DV, Wright P. – Drug resistance and Acanthamoeba keratitis: the quest for alternative protozoal chemotherapy. Eye 8: 555-563; 1994
  11. Illingworth CD, Cook SD – Acanthamoeba keratitis. Surv. Ophthalmol. 42: 493-508; 1998
  12. Lim N, Goh D, Bunce C, Xing W, Fraenkel G, Poole TRG, Ficker L – Comparison of polyhexamethylene biguanide and chlorexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am.J.Ophthalmol. 145: 130-135; 2008
  13. Moore MB, Mc Culley JP, Kaufmann HE, Robin JB – Radial keratoneuritis as a presenting sign in Acanthamoeba keratitis. Ophthalmology 93: 1310-1315; 1986
  14. Narasimhan S, Madhavan HN, Lily T – Development and application of an in vitro susceptibility test for Acanthamoeba species isolated from keratitis to polyhexamethylene biguanide and chlorexidine. Cornea 21: 201-205; 2002
  15. Niederkorn JY – The role of the innate and adaptative immune resposnses in Acanthamoeba keratitis. Arch.Immunol.Ther.Exp. (Warsz) 50: 53-59; 2002
  16. Seal DV, Hay J, Kirkness CM – Chlorexidine or polyhexamethylene biguanide for Acanthamoeba keratitis. Lancet 345: 136; 1995
  17. Seal DV, Hay J, Kirkness C, Morrell A, Booth A, Tullo A, Ridgway A, Armstrong M  – Successful medical therapy of Acanthamoeba keratitis with topical chlorexidine and propamidine. Eye 10: 413-421; 1996
  18. Schuster FL, Guglielmo BJ, Visvesvara GS – In vitro activity of miltefosine and voriconazole on clinical isolates of free-living amoebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J.Eukaryot.Microbiol. 53: 1212-126; 2006
  19. Tirado-Angel J, Gabriel MM, Wilson LA, Ahearn DG – Effects of polyhexamethylene biguanide and chlorexidine on four species of Acanthamoeba in vitro. Curr. Eye Res. 15: 225-228; 1996
  20. Wysenbeek YS, Blank-Porat D, Harizman N, Wygnanski-Jaffe T, Keller N, Avni I – The reculture technique: individualizing the treatment of Acanthamoeba keratitis. Cornea 19: 464-467; 2000
Condivi con
06/01/2014
Nessun commento
Tag:, ,